Slides
Page 1
1 R&D Day Presentation December 12th, 2024 (TSE : 4587) Copyright @2024 PeptiDream Inc. All Rights Reserved
Page 2
2 This presentation contains forward-looking statements. These forward-looking statements are current plans, forecasts, assumptions and strategies based on currently available information. There are various inherent risks as well as uncertainties involved. The actual results of business performance may differ from those forecasts due to various factors. These factors include, but are not limited to: (1) risks of delays, interruptions or failures associated with drug discovery and development; (2) risks of unexpected program disruptions or terminations due to changes in client policies; (3) risks associated with manufacturing products and the procurement of raw materials; (4) the impact of reduced competitiveness due to the competitors and competing technologies; (5) declining product sales capabilities; (6) adverse rulings in infringements or significant litigation against our Group's intellectual property rights; (7) adverse changes in economic conditions and related laws and regulations; and (8) fluctuations in interest rates and currency exchangerates. The information in this material with respect to drugs (including those under development) is not intended to provide advertising or medical advice. This material is intended to provide information on our Group's business and is not intended to solicit investment in securities. PeptiDream assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information. Forward-Looking Statements
Page 3
3 Today’s Agenda Radiopharmaceuticals Non-Radiopharmaceuticals Innovations in Our Platform Technologies 01 02 03
Page 4
4 Our Key Areas of R&D Focus Focused on Rapidly Growing a Deep Pipeline of Targeted Therapeutics and Diagnostics Radiopharmaceuticals (RI) Targeted RadioTherapy Non-Radiopharmaceuticals Growing the Next-Generation of Oral Peptide Therapeutics and Non-RI Peptide Drug Conjugates Cancer Targeting Peptide Ligand + Radioisotope (RI) RI Peptide Therapeutics Peptide Drug Conjugates (PDCs) Oligonucleotides Small Molecules Others Diagnostic Radionuclides Therapeutic Radionuclides Combining the powerful tumor targeting ability of macrocyclic peptides with the cell killing ability of RI Tumor Targeting Peptide Broad range of disease and therapeutic applications Peptide Targeted delivery of various non-RI payloads Tissue Targeting Peptide Tumor Targeting Peptide Target Binding Peptide
Page 5
Radiopharmaceuticals (RI) 01
Page 6
6 Target-specific ligand Linker Chelator Cancer cell ≡ Radioactive Rays Cancer targeting peptide ligand + Radioisotope (RI) Concept of Targeted Radiotherapy Advantages of Targeted RadiotherapyRadioisotope: Alpha (α) and Beta (β) Isotopes α α emitters β β emitters Radioisotopes kill cancer cells via DNA strand breaks ✓ Higher LET* (80-100 kEv/μm) (double strand breaks) ✓ Shorter range (20-80μm) ✓ Lower LET (0.2-0.5 kEv/μm) (single strand breaks) ✓ Longer range (2-11.5mm) Delivery of RI selectively to tumors RI Radioisotope (RI) Radiopharmaceuticals Targeted Radiotherapies – Revolutionizing How We Treat Cancer Source: 1) PeptiDream’s in-house analysis. 2) F. Zhuravlev. Curr Radiopharm., 2021, 14, 374-393. B.M. Privé, et al., Eur J Nucl Med Mol Imag., 2023, 50, 1906-1918. 3) J. Karlsson, et al., Front. Med., 2022, 1071086. M. Barok, et al., Breast Cancer Res., 2014, 16: 209. M.E. Autenrieth, et al., Eur J Nucl Med Mol Imaging., 2018, 45, 1364-1371. C.A. Kunos, et al., Front. Oncol., 2019, 9: 00180. 4) N.A. Ridge, et al., Adv Radiat Oncol., 2022, 7, 100936; R.B. Patel, et al., Sci Transl Med., 2021, 13(602), eabb3631. Brain, Skin, Liver, Kidney, Colon, Pancreas, Uterine, etc. Stromal cell, etc. Breast, Bladder, Ovarian, etc. Lung, Prostate, etc. Why Peptide As Ligand Difficult to Address by ADC1) Prior Diagnosis Is Essential2) Concern of Treatment Resistance3) Difficult to Address by Immuno-Oncology4) Favorable Pharmacokinetics (PK) Profile Fast Renal Clearance Lower Immunogenicity and Toxicity High Affinity and Specificity for Target Receptor Versatility and Ease of Synthesis/ Modification
Page 7
7 Power of Combining Diagnostic and Therapeutic Source: 1) in-house data. 2) K. Herrmann, et al., Lancet Oncol., 2020, 21, e146-e156. 3) C. Kratochwil, et al., Journal of Nuclear Medicine, Aug 2016, 57 (8), 1170-1176. Note: ePOC: early Proof-of-Concept Rapidly establish tumor targeting and in vivo efficacy of best peptide candidate in animal tumor models Pre-Clinical Development Phase 0 Theranostics (Thx) The same peptide-conjugate can be utilized for both diagnosis and treatment by just changing the RI Radioisotope for Diagnosis (Dx) Radioisotope for Treatment (Tx) Phase 1/2 Dx 1) 2) Dx Tx Candidate A Targeting Peptide Chelator Dx Simpler mechanism of Tx-RI, confirmation of Dx-RI’s delivery to the cancer lesion increases the certainty of drug efficacy and safety More efficiently design Ph1/Ph2 studies by leveraging Ph0 results Unique Theranostic approach of targeted-radiopharmaceuticals, allows for the quickest path to human ePoC, accelerating overall product development Cancer Patients Cancer Patients Clinical DevelopmentHuman ePoC “Rapid Validation” “De-risk” “Accelerate” Tx RI-Specific Quickest Path to Product Development Candidate Compounds Candidate B Dx Tx Candidate C Dx Tx Candidate D, E… Inject to Xenografted Mouse Evaluate Clear Detection of Tumor, Rapid Renal/Blood Clearance, Specific Distribution in Tumor, and Anti-tumor Effects 1 hr Post-dosing 4 hr Post-dosing 24 hr Post-dosing 48 hr Post-dosing Administer Small Dose of Dx-RI and Generate Human Imaging Data Evaluate Distribution in the Body and Accumulation in Cancer Cells Dx Tx Before Therapy After 3 Cycles Before Therapy After 3 Cycles3) 3) PET-CT Imaging
Page 8
8 Rapidly Growing Targeted Radiotherapy Field Market Size 1) (2022) $8.4bn (2030E) $29.4bn (CAGR: 19.5%) Note: 1) Market size estimates based on Fortune Business Insights (Nuclear Medicine Market Size, Share & COVID-19 Impact Analysis 2023-2030), 2) 2024 Q1 Sales of $310mm (+47% in Q1), Q2 Sales of $345mm (+44% in Q2) and Q3 sales of $386mm (+51% in Q3), annualized sales will exceed $1bn, 3) Including potential milestone payments Simple, Powerful MoA Compelling Therapeutic Approach True Precision Medicine • Limited treatment resistance • Overcoming tumor heterogeneity • “See it & Treat it” by Theranostics • Efficient & accurate screening of patients Clinical & Commercial Success Driving Further Excitement, Investment and Market Entry Lutathera® Approval (2018): Neuroendocrine Tumors (First key Targeted RI therapy that established the market) Pluvicto® Approval (2022): Prostate Cancer (Annualized $1bn+ Sales in 2024 2); aims multibillion blockbuster in mid-to-long term) PeptiDream – The Center of Innovation in RI Targeted Therapy Lutathera® & Pluvicto® Acquired AAA and Endocyte in 2018 Mariana Oncology in May 2024 (Total of ca. $7.75bn)(3) Acquired Noria and PSMA Therapeutics in 2021 Acquired in Oct. 2023 (ca. $1.4bn) Acquired in Mar. 2024 (ca. $2.4bn) Acquired in Dec. 2023 (ca. $4.1bn) Accelerating entry of biopharma into RI therapies field, through a sequence of acquisitions PeptiDream has been chosen as key collaboration partner by a multitude of leading players in this field and continues to build extensive partnered and internal pipeline programs Collaboration with PeptiDream in Sep. 2023
Page 9
9 Radiopharmaceuticals – PeptiDream Group RI Market Landscape PeptiDream + PDRadiopharma Business Model High Barrier to Market Entry Only 2 Licensed RI Companies • Strict Regulations/ Compliance • Supply Chain Requirement, etc. Partnering with a Local Company is Essential for Global Pharma to Commercialize Their RI Products Expanding Dx & Tx Applications Growing Demand of RI Challenges by Each Region • Regulations/ Compliance • Supply Chain Requirement Develop In-house Programs Develop Collaboration Programs In-licensing/Service Agreements • With collaboration partners, discover and develop a pipeline of high-value partnered program. • Were possible, retain the Japan rights to these collaboration discovery programs. • Partner with companies to bring their radiopharmaceutical products into the Japan market. Discovery Commercialization Japan Global Uniquely Positioned with Multiple Paths to Drive Value Creation Rapidly growing number of RI companies to potentially partner with PD+PDR • Discover and develop an internal pipeline of high-value peptide-RI programs. Create a Robust Development Pipeline!
Page 10
10 Pipeline Overview (Radiopharmaceuticals) Note: Above list only includes major pipeline programs in IND or later stages. PeptiDream is engaged in various pre-clinical programs as well Disease Area Pipeline Pre-clinical P0 P1 P2 P3 Partner (Japan) (Overseas) Malignant Brain Tumors 64Cu-ATSM Ph3 Ongoing － Prostate Cancer 177Lu/64Cu-PSMA I&T Bridging Study Prep. Ph3 Completed (Tx) Ph3 Ongoing (Dx) Malignant Glioma 177Lu-Integrin (FF58) － Ph1 Ongoing Oncology Novartis Program #2 － IND-enabling study Hepatocellular Carcinoma 225Ac/68Ga-GPC3 (RYZ801/811) Global Study Prep. Ph0 / IND-filing Renal Cell Carcinoma 225Ac/64Cu-CA9 (PD-32766) (In-house) Ph0 / IND- enabling － Oncology Novartis Program #3 － IND-enabling study Oncology 225Ac/64Cu-CLDN18.2 (PD-29875) (In-house) IND-enabling － Oncology RayzeBio Program #2 － Selected Clinical Dev. Candidate Solid Tumor 225Ac-Cadherin3 Ph1 back to Pre-clinical － Alzheimer’s Disease 18F-flortaucipir (Tauvid®) NDA Filed Marketed Various Cancers 18F-PD-L1 (BMS-986229) － Ph1 Completed IND-enabling / Ph0 Ph1 Ph2 Ph3Disease Area Pipeline Theranostics / TherapeuticsDiagnostics Development Stage Japan (Bridging Study (Planning))
Page 11
11 CONFIDENTIAL ✓ Maximum tolerated dose (MTD) was considered to be 99MBq/kg (30, 60, 99, 150 tested) - 18 patients who received 64Cu-ATSM were included in the primary analysis ✓ 64Cu-ATSM safe and well tolerated. No serious adverse events observed ✓ Median OS was 29.4 months and 1-year OS was 76.6% 5 out 9 patients with glioblastoma (grade3/4) who received 64Cu-ATSM survived for more than 1 yr (standard: ~30-40%) 64Cu-ATSM Program Program Overview Source: LinqMed and PeptiDream company disclosures; 1) Hiroaki Kurihara, et al. Abstract: Phase I clinical trial of 64Cu-ATSM for malignant brain tumors, ASCO (American Society of Clinical Oncology) 2024; JRCT (Japan Registry of Clinical Trials) website 64Cu-ATSM Program Overview Target and Indication Indication (# of Patients) Glioblastomas, astrocytomas, oligodendrogliomas In Japan, there are 4,000-5,000 new cases per year Target Hypoxic tumor microenvironment Remarks ✓ 5-year OS rate of 15.5%, median OS of 18 months. ✓ Recurrence rate of 51% ✓ Lack of effective treatments for patients with recurrent malignant brain tumors. Phase 1 STAR-64 Clinical Trial Results – Presented in June 2024 1) 64Cu-ATSM (Tx) • 64Cu-ATSM is a small molecule diacetyl-bis (N4-methylthiosemicarbazone) conjugated to the radioisotope Copper 64 • PDRadiopharma and LinqMed partnered for the clinical development, regulatory filing and commercialization of 64Cu-ATSM in Japan • LinqMed leads development activities • PDRadiopharma will lead the regulatory filing and commercialization Primary Endpoint: Assess dose-limiting toxicity Secondary Endpoint: Overall Survival (OS) Progression-free Survival (PFS) Pharmacokinetics & Effective Radiation Dose
Page 12
12 CONFIDENTIAL 64Cu-ATSM Program Current Clinical Development Status & Timeline Source: LinqMed and PeptiDream company disclosures, JRCT (Japan Registry of Clinical Trials), Ministry of Health, Labour and Welfare (MHLW) Phase 3 Clinical Trial Overview Recurrent High-grade Glioma Patients (Glioblastoma, Grade 3/4 Astrocytoma, Grade 3 Oligodendroglioma) (56 Patients Aged 18 to 75) 64Cu-ATSM 100MBq/kg (once a week for 4 weeks) Best Physician’s Choice (BPC) Temozolomide (TMZ) or Bevacizumab Primary Endpoint: Overall Survival (OS) Secondary Endpoint: Progression-free Survival, Response Rate, Adverse Event Expression Rate, KPS non-deterioration Rate R 1:1 1-year Follow-up Phase 3 Clinical Trial – Expected Timeline ✓ Initiated the Phase 3 Clinical Trial in Jun 2024 ✓ Patient enrollment is currently ongoing 2027~ Reference – SAKIGAKE Designation System • “Strategy of SAKIGAKE” formed by the Ministry Project Team of MHLW to lead the world in the practical application of innovative medical products • SAKIGAKE Designation System: promoting R&D in Japan aiming at early practical application for innovative pharmaceutical products, medical devices, and regenerative medicines • Designation Criteria: 1) Having firstly developed in Japan and planned an application for approvals, 2) Prominent effectiveness (i.e. radical improvement compared to existing therapy) can be expected Anticipated Product Filing Timing
Page 13
13 CONFIDENTIAL 177Lu-PSMA-I&T / 64Cu-PSMA-I&T Program Overview of Overseas Phase 3 Trial and Expected Clinical Development Timeline in Japan Source: Curium and PeptiDream disclosures, ClinicalTrials.gov. Note: 1) ARDT: Androgen Receptor (AR)-directed Therapy, 2) mCRPC: metastatic Castration-Resistant Prostate Cancer Category Targeted Radiotherapeutic (TRT) Target PSMA Clinical Phase Phase 3 ECLIPSE (NCT05204927) Trial Overview • ECLIPSE is a multi-center, open-label, randomized clinical trial • Comparing the safety and efficacy of 177Lu-PSMA-I&T versus hormone therapy (ARDT1)) in patients with mCRPC2) • Enrolled 439 patients (enrollment completed), across 51 trial sites in the US and Europe • Primary Endpoint: rPFS (Radiographic Progression Free Survival) • Secondary Endpoints: OS, rPFS 2, PFS, PFS 2, PSA Response Rate, Time to Skeletal Symptoms, Soft Tissue Progression, Time to Chemotherapy, Quality of Life Category Targeted Radiodiagnostic (TRD) Target PSMA Clinical Phase Phase 3 SOLAR RECUR (NCT06235099) Phase 3 SOLAR STAGE (NCT06235151) Trial Overview SOLAR RECUR • Testing the diagnostic performance in men with biochemical recurrence of prostate cancer • Estimated enrollment of 200 patients, across 22 trial sites in the US • Study Start: Apr 2024 SOLAR STAGE • Testing the diagnostic performance in men with newly diagnosed unfavorable intermediate- to high-risk prostate cancer • Estimated enrollment of 323 patients, across 17 trial sites in the US • Study Start: Apr 2024 Overseas Phase 3 Trial Overview 177Lu-PSMA-I&T (Tx) 64Cu-PSMA-I&T Recent Clinical Trial Updates ✓ In Nov 2024, Curium Announced 177Lu-PSMA-I&T Phase 3 ECLIPSE Trial Met Primary Endpoint ✓ Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients with PSMA-positive mCRPC 2) Expected Clinical Development Timeline in Japan Clinical Development to start in 2025
Page 14
14 Integrin αvβ3/5-targeting (FF-58) Program ProgramOverview Source: 1) GlioCure. https://www.gliocure.com/en/patients/glioblastoma/; 2) ClinicalTrials.gov. FF-58 Program Overview • FF-58 are novel Integrin αvβ3/5-targeting program, discovered by FujiFilm/ PDRadiopharma and licensed to Novartis/AAA • Dev./commercialization rights: Novartis (Global ex-Japan) Target and Indication Indication (# of Patients) Malignant glioma and others (Glioblastoma: 250,000 1)+ others) Target Integrin αvβ3/5 Remarks ✓ 177Lu-FF-58 is a radiopharmaceutical for the treatment of advanced or metastatic solid tumors (Phase 1) ✓ Phase 1 Trial is ongoing Clinical Trial Overview 2) 177Lu 177Lu-FF-58 (Tx) Title A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors ID NCT05977322 Study Type Interventional Phase Phase 1 Study Start Oct 6, 2023 Study Status Active, not recruiting Primary Completion Dec 16, 2024 (Estimated) Enrollment 6 Condition or Disease • Pancreatic Ductal Adenocarcinoma • Gastroesophageal Adenocarcinoma • Glioblastoma Multiforme (Purpose of This Study) • To test the safety and dosing of 177Lu-FF-58, a radioligand therapy for patients with advanced or metastatic tumors that express proteins known as integrins: alpha-v beta-3 integrin (αvβ3) and alpha-v beta-5 integrin (αvβ5)
Page 15
15 Glypican 3 (GPC3) As A Target for RI Therapy Source: RayzeBio and PeptiDream disclosures; 1) Y. Shimizu, et al., Cancer Sci., 2019, 111, 334–342.; *) Data obtained from www.proteinatlas.org Note: Created with BioRender.com Glypican 3 (GPC3) Biology Overview Why GPC3? GPC3 expression across different tumor types* • GPC3 is a member of the glypican family of cell-surface heparan sulfate proteoglycans • GPC3 is involved in several critical cellular processes including cell signaling, cell growth and proliferation and epithelial-mesenchymal transition (EMT), etc. • Its expression is tightly regulated, and abnormal expression can contribute to the progression of cancer ✓ GPC3 is highly expressed in patients with hepatocellular carcinoma (HCC) (~80%) 1) ✓ GPC3 shows minimal to no expression in normal tissues, making it an ideal target for RI Therapeutics Liver Cancer GPC3 forms a complex with Wnt and activates Wnt signaling leading to the HCC growth
Page 16
16 GPC3-Targeting (RYZ801 & RYZ811) Program ProgramOverview Source: 1) WHO the global cancer observatory, 2) J.M. Llovet, et al., Nat Rev Dis Primers., 2021, 7: 6., 3) RayzeBio Corporate Presentation September 2023. *): using 177Lu. RYZ801 & RYZ811 Program Overview • RYZ801/RYZ811 are novel GPC3-targeting macrocyclic peptide conjugated to a chelator • Discovered by PeptiDream in collaboration with RayzeBio • Dev./commercialization rights: PeptiDream (Japan), RayzeBio (Global ex-Japan) 225Ac RYZ811 (Dx) RYZ801 (Tx) 68Ga Target and Indication Indication (# of Patients) Hepatocellular carcinoma (HCC) ~905,0001) new cases in 2020 (830,180 deaths) Target Glypican 3 (GPC3) Remarks ✓ Hepatocellular carcinoma (HCC) is the 6th most common form of cancer worldwide2) ✓ High unmet need, limited treatment options Biodistribution and Tumor Targeting of RYZ801 in MouseHCC Tumor Model 3), *) Tumor Reduction Efficacy of RYZ801 in Mouse HCC Tumor Model 3) ✓ Single doses of 177Lu or 225Ac labelled RYZ801 show significant tumor reduction ✓ 225Ac demonstrated superior tumor reduction to 177Lu at doses 1,000 times lower
Page 17
17 GPC3-Targeting (RYZ801 & RYZ811) Program Latest Updates and Upcoming Milestones RYZ801 & RYZ811 Clinical Development Timeline Overview RYZ801 & RYZ811 Latest Updates Upcoming Milestone ✓ IND Filing by RayzeBio/BMS ✓ PeptiDream/PDRadiopharma intend to leverage the RayzeBio Ph1 clinical data to initiate bridging studies into Japan, to then participate with RayzeBio/BMS in a global Ph2 Study Initiation of Ph1 Study in 2025 1Q Compassionate Use Study (Dx + Tx) IND enabling study 2024 2H IND Filing Phase 1a/1b Tx & Dx Phase 2 (Pivotal) Tx & Dx Phase 1/2 Tx & Dx 2024 2H Data Bridging Data Bridging RayzeBio is wrapping one of the most extensive Ph0 studies ever
Page 18
18 Novartis RI Program #2 Program Overview Source: PeptiDream disclosures Novartis RI Program #2 Overview ✓ Initiated IND-enabling studies (announced in Oct 2023), and PeptiDream received $7.5mm (JPY1.1bn) Milestone Fee. ✓ IND-filing by Novartis Key Recent Updates Upcoming Milestone Initiation of Ph1 Study • Novartis RI Program #2 (target not disclosed) is a macrocyclic peptide conjugated to a chelator • Discovered by PeptiDream in collaboration with Novartis under the partners 2019 agreement • Dev./commercialization rights: Novartis (Global) RI for Tx RI for Dx Ref – Novartis Collaboration Agreement in 2019 • Peptide Drug Conjugate (“PDC”) collaboration agreement with Novartis announced in Jun 2019. • Under the agreement, PeptiDream uses its proprietary Peptide Discovery Platform System (PDPS) technology for the identification of novel macrocyclic/constrained peptides for uses as PDCs against multiple targets selected by Novartis. • Novartis has exclusive rights to the program peptides for radionuclide payloads/conjugates and certain small molecule payloads/conjugates for both therapeutic and diagnostic uses.
Page 19
19 Carbonic Anhydrase 9 (CA9) As A Target for RI Therapy Carbonic Anhydrase 9 (CA9) Biology Overview Why CA9? CA9 expression across different tumor types* • CA9 is a member of the carbonic anhydrase family of cell-surface transmembrane proteins • CA9 catalyzes the reversible hydration of carbon dioxide (CO2) into bicarbonate ions (HCO3 -) and protein (H+). This reaction is essential for various cellular processes, including respiration, pH regulation, and ion transport • Its expression is tightly regulated, and abnormal expression can contribute to the progression of cancer ✓ CA9 is highly expressed in renal cell carcinoma (RCC) (~90%)1), as well as many other cancers, including breast cancer (TNBC), and head and neck cancer, glioblastoma, ovarian, and colorectal cancer 2) ✓ CA9 shows minimal to no expression in normal tissues, making it an ideal target for RI Therapeutics CA9 is not expressed in healthy renal tissue but is expressed in most clear cell renal cell carcinomas (ccRCC) through HIF-1α accumulation driven by hypoxia and inactivation of the VHL gene. Kidney Cancer Source: 1) B. Soyupak, et al., Urol Int., 2005, 74, 68-73. J. Tostain, et al., Eur. J. Can., 2010, 46, 3141-3148. 2) R. Ronca, et al., Biochim Biophys Acta (BBA)., 2024, 1879, 189120.; *) Data obtained from www.proteinatlas.org Note: orgCreated with BioRender.com (VHL loss function)
Page 20
20 CA9-Targeting (PD-32766) Program ProgramOverview PD-32766 Overview • PD-32766 is a novel CA9-targeting macrocyclic peptide conjugated to a chelator • Discovered by PeptiDream as an internal program • Dev./commercialization rights: PeptiDream (Global) 177Lu/225Ac PD-32766 (Dx) PD-32766 (Tx) 64Cu/68Ga Target and Indication Indication (# of Patients) Clear cell Renal Cell Carcinoma (ccRCC) ~390,000 1) new cases in 2020 Target Carbonic Anhydrase 9 (CA9) Remarks ✓ CA9 is highly expressed in ~90% of ccRCC patients 2) ✓ Most common type of kidney cancer ✓ 5-year survival rate for patients with RCC of 49.8% 3) Selective and Strong Binding to CA9 Clearly Detects ccRCC Tumors with Rapid Renal Clearance ✓ PD-32766 shows strong and selective binding to CA9 1 hr Post-dosing 4 hr Post-dosing 24 hr Post-dosing 48 hr Post-dosing PET-CT Imaging of 64Cu-PD-32766 (IV, 4.3 MBq) in VMRC-RCW Xenograft Mice ✓ 64Cu-PD-32766 showed specific imaging of CA9 expressing tumors Source: Mizukoshi et al. AACR 2024 presentation; 1) L. Bukavina, et al., Eur Urol., 2022, 82, 529-542. 2) B. Soyupak, et al., Urol Int., 2005, 74, 68-73. J. Tostain, et al., Eur. J. Can., 2010, 46, 3141-3148. 3) Data from The Cancer Genome Atlas Program(TCGA).
Page 21
21 CA9-Targeting (PD-32766) Program ProgramOverview Strong and Specific Distribution to Tumor 177Lu-PD-32766 – Robust in vivo Anti-Tumor Effects ✓ Both64Cu-PD-32766 and 177Lu-PD-32766 shows strong and specific biodistribution to tumor Biodistribution of 64Cu-PD-32766 (4.3 MBq) and 177Lu-PD-32766 (2.8 MBq) in VMRC-RCW Xenograft Mice 177Lu-PD-3276664Cu-PD-32766 Source: Mizukoshi et al. AACR 2024 presentation; 2) Wahl RL, Sgouros G, Iravani A, et al. J Nucl Med. 2021 Dec;62(Suppl 3):23S-35S.; 3) B Emami, J Lyman, A Brown, et al. Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22.; 4) Lawrence BM, Ellen DY, Andrew J, et al. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9 Note: 1) For dosimetry, SD rats were injected intravenously with 2.3 MBq of 64Cu-PD-32766; BLOQ = Below quantifiable limit; EBRT = External beam radiotherapy • Efficacy assessed in VMRC-RCW xenograft mice • Each dose at 30 MBq, which in mice is equivalent to 7.32 GBq in human, which is a clinically used dose 0 7 14 21 28 35 42 49 0 300 600 900 1200 Days after 1st dose Tumor size (mm3) Saline, QW x3 177Lu-PD-32766, single dose 177Lu-PD-32766, QW x3 Tumor growth Weight Change Ratio 0 7 14 21 28 35 42 49 90 95 100 105 110 115 Days after 1st dose Weight change ratio (%) Rapid Blood Clearance and Large Safety Margin Male Female T1/2 (h) 0.48 0.04 0.57 0.10 C0 (ng/mL) 9112 334 7372 2126 AUClast (h*ng/mL) 4353 320 4181 465 Organ Absorbed dose (mGy/MBq) EBRT limit (Gy) Allowed dose (GBq) Kidneys 0.159 232) 145 Urinary bladder wall 0.060 653) 1078 Lower large intestine 0.015 453) 2961 Small intestine 0.013 403) 2985 Liver 0.010 302) 3036 Stomach wall 0.008 452) 5747 Upper large intestine 0.006 453) 7732 Spleen 0.005 402) 8097 Heart wall 0.004 262) 7242 Red marrow 0.003 22) 671 Lungs 0.002 204) 8969 Plasma Concentration and PK Parameter of PD-32766 (2.5 mg/kg) in Rats Predicted Human 64Cu-PD-32766 Dosimetry1) Based on Rat Biodistribution • Predicted clinical dose of 64Cu-PD-32766: 148 MBq • Human estimated effective dose (male): 0.0118 mSv/MBq PD-32766 ✓ Showed excellent PK and a clean distribution profile ✓ Clear in vivo anti-tumor effect and good tolerability in a clinically relevant ccRCC xenograft mouse model ✓ Potential Best-in-Class
Page 22
22 CA9-Targeting (PD-32766) Program Clinical Development Progress and Upcoming Milestones PD-32766 64Cu-PD-32766 IND enabling studies Clinical Research (Phase 0) IND-Filing Phase 1 Tx & Dx DataBridging Leverage Phase 0 results to more efficiently design Ph1/Ph2 studies Accelerate Generate human imaging data using the paired diagnostic agent directly in target patient population De-Risk PD-32766 Clinical Development Timeline Overview PD-32766 Latest Updates Upcoming Milestone Enrollment Completed Data Analysis Ongoing ✓ Ph0 study (initiated in June 2024) enrolled a total of five ccRCC patients, that were each administered 64Cu-PD-32766 followed by imaging by PET/CT (JRCT trial identifier: jRCTs031240046) ✓ Ph0 study’s key objectives to evaluate the safety, pharmacokinetics, and exposure dose of PET/CT with 64Cu-PD-32766 in patients with newly diagnosed, relapsed or suspected to have relapsed ccRCC Ph0 Study Results To Be Presented at ASCO-GU 2025 (Feb 2025) Planning for Ph1 Note: ASCO-GU (American Society of Clinical Oncology’s Genitourinary Cancers Symposium)
Page 23
23 Claudin 18.2 (CLDN18.2) As A Target for RI Therapy Claudin 18.2 (CLDN18.2) Biology Overview Why CLDN18.2? CLDN18 expression across different tumor types* • Claudin 18 Isoform 2 (CLDN18.2) is a member of the claudin family of proteins involved in the formation of tight junctions between cells • CLDN18.2 is essential for maintaining healthy interactions between cells and thus the integrity of tissues and organs. In the stomach, it plays a crucial role in regulating paracellular transport of ions and water, helping to maintain the stomachs acidic environment needed for normal digestion • Its expression is tightly regulated, and abnormal expression can contribute to the progression of cancer, as well as the ability of cancer cells to invade surrounding tissues, spread to other organs, and develop resistance to chemotherapy and other treatments ✓ CLDN18.2 is highly expressed in gastric cancer (~40%)2), as well as many other cancers, including pancreatic cancer and other types of solid tumors ✓ Additionally, CLDN18.2 becomes more exposed under tumor conditions with loss of cellular integrity, making it an ideal target for RI Therapeutics Claudin 18.2Nonmalignant Cells Cancer Cells Basement membrane Gastric epithelial cells Gastric cancer Expose to cell surface of whole membrane due to perturbations in cell polarity 1) Gastric Cancer Pancreatic Cancer Source: 1) I. Nakayama, rt al., Nat Rev Clin Oncol., 2024, 21, 354-69. 2) R. Waters, et al., JCO Precis Oncol., 2024, 8, e2300543.; *) Data obtained from www.proteinatlas.org Note: Created with BioRender.com
Page 24
24 0 10 20 30 40 50 0 200 400 600 800 1000 Tumor size The day after 1st dosing Tumor size (mm3) Saline 177Lu-PD-29875 QWx1 177Lu-PD-29875 QWx3 Gemcitabin 0 10 20 30 40 50 80 90 100 110 120 130 Weight change The day after 1st dosing Weight change Saline 177Lu-PD-29875 QWx1 177Lu-PD-29875 QWx3 Gemcitabin CLDN18.2-Targeting (PD-29875) Program PD-29875 Overview • PD-29875 is a novel CLDN18.2-targeting macrocyclic peptide conjugated to a chelator • Discovered by PeptiDream as an internal program • Dev./commercialization rights: PeptiDream (Global) 177Lu/225Ac PD-29875 (Dx) PD-29875 (Tx) 64Cu/68Ga Target and Indication Indication (# of Patients) Claudin 18.2 positive gastric cancer ~1.1 million new cases in 2020 1) Target Claudin 18.2 (CLDN18.2) Remarks ✓ 5th most common form of cancer. ✓ Predicted to have 1.8 million new cases annually by 2040. ✓ Remains high unmet medical need. ✓ CLDN18.2 is a clinically validated target for cancer. In-vivo Imaging of PD-29875 in Tumor Mouse Model ✓ Exhibits high affinity and selectivity for CLDN18.2 target ✓ Showed highly specific targeting and uptake in CLDN18.2 positive tumors in tumor mouse models, with minimal non-tumor accumulation (e.g. kidney, etc.) ✓ Showed strong tumor reduction efficacy, supporting the decision to take the program into IND-enabling studies and human imaging Tumor In-vivo Tumor Reduction Efficacy of PD-29875 in Tumor Mouse Model 0 10 20 30 40 50 80 90 100 110 120 130 Weight change The day after 1st dosing Weight change Saline 177Lu-PD-29875 QWx1 177Lu-PD-29875 QWx3 Gemcitabin (Tumor Size) (Weight Change) ProgramOverview Source: 1) E. Morgan, et al., eClinicalMedicine. 2022, 47, 101404.
Page 25
25 CLDN18.2-Targeting (PD-29875) Program Latest Updates and Upcoming Milestones PD-29875 64Cu-PD-29875 IND enabling studies Clinical Research (Phase 0) IND-Filing Phase 1 Tx & Dx DataBridging Leverage Phase 0 results to more efficiently design Ph1/Ph2 studies Accelerate Generate human imaging data using the paired diagnostic agent directly in target patient population De-Risk PD-29875 Clinical Development Timeline Overview PD-29875 Latest Updates Upcoming Milestones ✓ Clinical development candidate arising from PeptiDream’s ongoing internal peptide radiopharmaceutical discovery and development efforts ✓ PeptiDream has initiated IND-enabling studies of PD-29875 and intends to initially develop the therapeutic (225Ac-PD-29875) and paired diagnostic imaging agent (64Cu-PD-29875) for the diagnosis and treatment of gastric cancer First-in-Human Ph0 Imaging Studies of 64Cu-PD-29875 in 2025 Key Results of PD-29875 Pre-clinical Study To Be Presented at Medical Conferences in 2025
Page 26
26 Other RI Programs – Key Recent Updates Source: Company disclosures Note: EANM (European Association of Nuclear Medicine) Novartis Program #3 RayzeBio Program #2 PPMX CDH3 Program ✓ Initiated IND-enabling studies, with PeptiDream receiving a $7.5mm (JPY1.1bn) Milestone Fee in Jul 2024 (Recent Updates) (Brief Program Overview) • Novartis RI Program #3 (Target: Undisclosed) discovered by PeptiDream in collaboration with Novartis (under 2019 RI collaboration agreement) • Dev./commercialization rights: Novartis (Global) (Recent Updates) (Brief Program Overview) (Recent Updates) (Brief Program Overview) ✓ No publicly disclosed news in 2024, with BMS’s acquisition of RayzeBio ✓ Announced preclinical data for the treatment of solid tumors at EANM’24 in Oct 2024 • PPMX CDH3 Program (PPMX-T002) is a radioisotope labelled antibody targeting cadherin 3 (CDH3), which is highly expressed on solid tumors including head and neck, ovarian, pancreatic and lung cancers • Changed the RI payload from Yttrium 90 (90Y), a beta emitter, to Actinium 225 (225Ac) an alpha emitter in 2024 • RayzeBio Program #2 (Target: Undisclosed) discovered by PeptiDream in collaboration with RayzeBio (under 2020 RI collaboration agreement) • Dev./commercialization rights: PeptiDream (Japan), RayzeBio/BMS (Global ex-Japan)
Page 27
Non-Radiopharmaceuticals 02
Page 28
28 Non-Radiopharmaceuticals – Overview Note: * PDBID: 1FMK Merck & Co., Inc., Rahway, NJ, USA Peptide TherapeuticsPeptide Therapeutics Other Targeted Peptide Conjugates (Approach) Intracellular Extracellular Oral Injectables (Dosing) vs. vs. Oligonucleotides (siRNA / ASO / HDO) Small Molecules (Cytotoxic Compounds) Others Broad range of disease and therapeutic applications Peptide targeted delivery of various non-RI payloads Tissue Targeting ★ ★ ★ ✓ Brain, Kidney, Heart, Muscle, Lung, etc. Tumor Targeting ✓ PDCs as a compelling alternative to ADCs Target Binding Peptide * ✓ Enables new therapeutic modalities ‒ Multi-functional Peptide Conjugates (MPCs) ‒ Protein Degraders ‒ Immune Recruiters, etc. ✓ Excellent affinity & selectivity ✓ Unique epitopes & MOAs ✓ Differentiating PK & ADME characteristics ✓ Oral Administration & other routes possible ✓ Enable small molecule discovery Selected Partners for Non-RI Programs Biohaven
Page 29
29 Disease Area Pipeline Pre-clinical P1 P2 P3 Partner (Japan) (Overseas) Clinical Programs Acromegaly GhR Antagonist (AZP-3813) － Ph1 Completed Oncology PD-L1 Inhibitor － Ph1 Completed Multiple Myeloma CD38-ARMTM (BHV-1100 + NK) － Ph1a/1b Ongoing Not Disclosed Merck Program #1 Not Disclosed Ph1 Ongoing Inflammatory Diseases Merck Program #2 Not Disclosed Ph1 Ongoing COVID-19 S2-protein Inhibitor (PA-001) Clinical Research Completed Ph1 Ongoing Selected PC Programs Obesity/ SMA/DMD/ Muscle Disorders Myostatin Inhibitor (In-house) Pre-clinical Obesity & Bioavailability － Allergic Diseases KIT Inhibitor (MOD-B) IND-enabling study － Pipeline Overview (Non-Radiopharmaceuticals) Note: Above list only includes major pipeline programs in clinical stage and selected pre-clinical stage; 1) Merck & Co., Inc., Rahway, NJ, USA IND-enabling Ph1 Ph2 Ph3Disease Area Pipeline Biohaven 1) 1) Development Stage
Page 30
30 GhR Inhibitor (AZP-3813) Program AZP-3813 Overview Program Overview • AZP-3813 is a novel bicyclic peptide growth hormone receptor (GhR) antagonist discovered at PeptiDream and licensed to Amolyt Pharma in 2021. • Amolyt is developing AZP-3813 as add-on therapy for the treatment of acromegaly in patients insufficiently controlled with somatostatin analogs (SSA). ✓ Completed a Phase 1 study, initiated in Jun 2023, confirming the safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-3813 in healthy subjects. ✓ Amolyt acquired by AstraZeneca in 2024 ✓ AZP-3813 under AZ’s rare disease division Alexion (ALXN2420). Target and Indication Indication (# of Patients) Acromegaly; Neuroendocrine neoplasms >56,0001) (Acromegaly); underdiagnosed Target Growth-hormone receptor (GhR) Remarks Excessive secretion of growth hormone (GH) leads to • Abnormal increase in IGF-1 levels • Enlargement of the hands/feet/jaw, and various metabolic disorders/ complicating diseases Source: Poster SAT-042 Allas et al, ENDO 2024; Poster MON-110 Ravel et al, ENDO 2024 Note: 1) Grand View Research AZP-3813 ALXN2420 Mechanism of Action AZP-3813 Additive Effect of GhR Antagonist AZP-3813 on SSAs Additive Effect of AZP-3813 When Combined with Octreotide on IGF-1 Levels in Normal Rats; Data are mean of IGF-1 versus baseline + SEM (n=7/group) ✓ AZP-3813 demonstrated ability to decrease circulating levels of IGF-1 and an additive effect when combined with the SSA, Octreotide (20 μg/kg/day), in normal rats • SSAs suppress GH production • AZP-3813 binds to the GH receptor and blocks binding of GH • Two different mechanisms to reduce stimulation of the liver to produce IGF-1 AZP-3813 (3 mg/kg) Octreotide (20 μg/kg/day) AZP-3813 (3 mg/kg) + Octreotide (20 μg/kg) Octreotide effect (20 μg/kg/day) = -10% AZP-3813 effect (3 mg/kg) = -13%
Page 31
31 GhR Inhibitor (AZP-3813) Program Phase 1 Summary – Study Completed in 1H-2024 • Phase 1 randomized, double-blind, placebo- controlled single ascending dose (SAD; 3 – 120mg) and multiple ascending dose (MAD; 10-120mg; once- a-day for 14 days) study was conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics (serum IGF-1 levels) Source: Poster SAT-042 Allas et al, ECE 2024; Poster MON-110 Ravel et al, ENDO 2024 Phase 1 Study Safety and Tolerability ✓ Good tolerability with no safety concerns ✓ No serious adverse event (SAE), or treatment-emergent adverse event (TEAE) leading to study discontinuation. All TEAEs reported were mild or moderate in severity ✓ No clinically significant abnormalities with respect to safety labs, vital signs and ECG Pharmacokinetics & Pharmacodynamics ✓ Cmax and AUC increased in a dose proportional manner ✓ Half life (t1/2) ~20-22h consistent with QD (once a day) dosing Upcoming Milestone (SAD) (MAD) ✓ Repeated administration of AZP-3813 induced a dose related decrease in IGF-1 levels well within the level of reduction expected to result in excellent control of IGF-1 levels in patients with acromegaly Phase 2 Mean % Change from Baseline in Serum IGF-1
Page 32
32 Therapeutic Programs Oral PD-L1 Program and CD38-ARM/IgG Bifunctional Program PD-L1 Program Update CD38-ARM/IgG Bifunctional Program Update • In April 2022, initiated a Phase 1 study investigating safety, tolerability, and PK in healthy volunteers of an oral peptide inhibitor of PD-L1 Indication: Immuno-Oncology Indication: Multiple Myeloma • As announced in October 2023, BMS notified PeptiDream of their election to not continue clinical development of this program for business reasons • PeptiDream recently received remaining data from the Ph1 study and is still analyzing the data and considering next options • The underlying peptide series discovered by PeptiDream is still being utilized in the imaging agent (F18-BMS-986229) • PeptiDream free to pursue any therapeutic modalities against PD-L1 Target: PD-L1 Target: CD38 & IgG • ClinicalTrials.gov Identifier: NCT04634435 • Phase 1 study conducted at Dana-Farber Cancer Institute. • This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 in the peri-transplant setting in MM patients with minimal residual disease (MRD+) in first or second remission • In Oct 2021, initiated a Phase 1a/1b clinical study in patients with multiple myeloma of a peptide targeting CD38 conjugated to a peptide targeting IgG (BHV-1100) Biohaven
Page 33
33 Merck Peptide Therapeutic Programs Two programs from PD/Merck collaboration have entered Phase 1 trials Note: Merck & Co., Inc., Rahway, NJ, USA Merck Program #2 Update Merck Program #1 Update • In Jun 2024, Merck initiated a Phase 1 clinical study of a peptide therapeutic candidate discovered using PeptiDream’s Peptide Discovery Platform System (PDPS) technology Indication: Inflammatory Diseases Indication: Not Disclosed • The Phase 1 study is being conducted to investigate the safety, tolerability, and pharmacokinetics in healthy volunteers • No ClinicalTrials.gov identifier for the Phase 1 study because it is being run in healthy volunteers • The Merck Program #2 originated from PeptiDream and Merck’s 2018 PDPS technology licensing agreement • Program has certain partner limitations on disclosable information Target: Not Disclosed Target: Not Disclosed • The Phase 1 study is being conducted to investigate the safety, tolerability, and pharmacokinetics in healthy volunteers • No ClinicalTrials.gov identifier for the Phase 1 study because it is being run in healthy volunteers • The Merck Program #1 originated from PeptiDream and Merck’s 2018 PDPS technology licensing agreement • Program has certain partner limitations on disclosable information • In Jul 2023, Merck initiated a Phase 1 clinical study of a peptide therapeutic candidate discovered using PeptiDream’s Peptide Discovery Platform System (PDPS) technology
Page 34
34 Corona Virus Spike-Protein Inhibitor (PA-001) Program PA-001 Overview Program Overview Target and Indication Indication Corona Virus (SARS-CoV2) Target Corona Virus S2 Spike Protein Remarks Clinical Study ✓ In Jul 2024, FDA has approved the IND application for the Phase 1 clinical trial of PA-001 ✓ On Oct 7th, 2024, PeptiAID announced the dosing of first subject in Phase 1 clinical trial of PA-001 ✓ Phase 1 results anticipated in H2-2025 • The Phase 1 study of PA-001 is designed to evaluate the safety, tolerability, and pharmacokinetics of PA-001 in healthy and elderly volunteers • No ClinicalTrials.gov identifier for the Phase 1 study because it is being run in healthy volunteers • PA-001 is a potent macrocyclic peptide inhibitor of the spike protein of SARS- CoV-2 and has shown broad efficacy against COVID-19 variants (alpha, beta, delta, omicron, and newervariants). • PA-001’s unique MoA has the potential for greater efficacywhen combined with existing and/or other COVID-19therapeutics • PA-001 program adopted by the Japan Agency for Medical Research and Development (AMED) as part of the “Research Program to Promote the Development of InnovativeTherapeutics for Emerging and Re-emerging InfectiousDiseases” • PA-001 is partnered with PeptiDream spinout
Page 35
35 Muscle cell membrane ActR2A/2BAlk4/5 Myostatin Inhibitor Program Program Overview Smad2/3 Muscle Atrophy Activation of target genes/proteins Pro/Latent Myostatin (GDF8) Myostatin (GDF8) GDF11 Activin Smad4 Nucleus ✓ PeptiDream has developed a series of potent macrocyclic and bridged macrocyclic peptide inhibitors of Myostatin ✓ Series candidates show varying degrees of selectivity for Myostatin over GDF11, with no binding to Activin ✓ Exhibit excellent pharmacokinetics, including high exposure in muscle tissues ✓ Efficacious administered either SC or orally, making them the first reported orally bioavailable myostatin inhibitors ✓ Originally program developed for DMD demonstrating therapeutic benefit in mouse models of DMD Myostatin/Activin Receptor Signaling Pathway Myostatin PeptiDream’sPortfolio of Macrocyclic Peptide Inhibitors of Myostatin • Myostatin (also known as growth differentiation factor 8, or GDF8), along with GDF11 and Activin, are members of the transforming growth factor-beta (TGFbeta) superfamily, and function in a complex process that regulates muscle growth and function • Myostatin has pro-, latent-, and mature- forms, and is regulated by a complex network of inhibitory proteins, as local autocrine and paracrine signaling likely plays a predominant role in regulating muscle homeostasis • Inhibitors of the Myostatin/GDF11/Activin signaling pathway investigated across a broad range of disorders, including DMD, SMA, ALS, cachexia, obesity and type II diabetes, as well as other metabolic and muscle diseases
Page 36
36 Therapeutic Inhibitors of Myostatin Pathway Source: Company disclosures and PeptiDream internal research Note: 1) M: Myostatin (GDF-8), G: Growth Differentiation Factor 11 (GDF-11), A: Activin Compound Company Obesity Development Status Modality Route of Admin Target Molecule Ligand 1) Receptor M G A ActRIIA/B PD Peptide PeptiDream Pre-clinical Macrocyclic Peptide PO, SC ✓ Bimagrumab Eli Lilly Ph2 Antibody IV ✓ GYM329 Roche/Chugai Ph2 Antibody SC ✓ Taldefgrobepalfa Biohaven Ph1 Adnectin-Fc SC ✓ ✓ ✓ Trevogrumab Regeneron Ph2 Antibody SC ✓ Garetosmab Regeneron Ph2 Antibody IV ✓ SRK-439 Scholar Rock Pre-clinical Antibody SC ✓ Apitegrumab Scholar Rock Ph2 Antibody IV ✓ PeptiDream Develops Potential First-in-class Oral Myostatin Inhibitor Development Landscape
Page 37
37 Oral Myostatin Inhibitor Program Preclinical Results of Obesity POC Study – Daily Oral Administration Lean Body Mass (LBM; Primary Endpoint) ✓ Daily oral administration of PD peptide showed strong preservation of lean body mass in obese animals treated with semaglutide. ✓ Lean body mass preserving effect of PD peptide was dose dependent. ✓ Semaglutide induced decreases in fat mass unaffected by PD-peptide. Body Weight Fat Mass Normal Control -10 -8 -6 -4 -2 0 % Change of Lean Body Mass ✱✱ ✱ 0 0.5 1.5 4.5 PD Peptide (mg/kg, PO) + Semaglutide (0.12 mg/kg, SC) Control -100 -80 -60 -40 -20 0 20 40 % Change of Fat Mass 0 1.5 4.50.5 PD Peptide (mg/kg, PO) + Semaglutide (0.12 mg/kg, SC) 2 6 10 14 18 22 26 -30 -20 -10 0 10 Days % Change of Body Weight Data are presented as Mean±SEM (N=8-10). *; P<0.05, **; P<0.01 vs vehicle group Obesity Model
Page 38
38 Oral Myostatin Inhibitor Program Preclinical Results of Obesity POC Study – Once-a-Week Oral Administration Lean Body Mass (LBM; Primary Endpoint) Body Weight Fat Mass Data are presented as Mean±SEM (N=9-10). *; P<0.05 vs vehicle group 2 6 10 14 18 22 26 -30 -20 -10 0 10 Days % Change of Body Weight Normal Control -8 -6 -4 -2 0 % Change of Lean Body Mass ✱ Control -100 -80 -60 -40 -20 0 20 40 % Change of Fat Mass 0 10 303 PD Peptide (mg/kg, PO) + Semaglutide (0.12 mg/kg, SC) 0 3 10 30 PD Peptide (mg/kg, PO) + Semaglutide (0.12 mg/kg, SC) ✓ Strikingly, weekly oral administration of PD peptide showed stronger preservation of lean body mass in obese animals treated with semaglutide compared to daily administration. ✓ Lean body mass preserving effect of PD peptide was dose dependent, and at higher doses, increased LBM above non- treated animals. ✓ Potential to dramatically transform how we manage weight loss. Obesity Model
Page 39
Innovations in Our Platform Technologies 03
Page 40
40 PDPS Incorporates Non-Canonical Amino Acids to Discover Macrocyclic Peptides with Drug-like Properties PeptiDream’s 3,000+ AAs *e.g. 10 positions with 20 building blocks 2010 = 10,240,000,000,000 different peptides in a library* Robust, cell-free synthesis derived by nature’s way of making peptides Each peptide “barcoded” via its mRNA/cDNA tagRandomized DNA Library Macrocyclic Peptides BINDELUTE AMPLIFY TRANSLATE x7 Power of Directed Evolution Round over round iterations enables the profiling of 10 trillion peptides at a time Customized kinetic and thermodynamic parameters enables customized discovery platform High throughput automation to maximize hit discovery rate Core PDPS Optimization Proprietary tRNAs to incorporation complex drug-like NCAAs Incorporation of Medicinal Chemistry strategies Development of novel scaffolds and conjugations to increase PTS of complex therapeutic MoA Next Generation Data Analysis Developing computational methodologies to enable more diverse starting points Development and integration of ML/AI models to reduce lead optimization cycle times DNA is the output. Enables massive NGS sequencing and dataset collection
Page 41
41 Increasing the Chemical Diversity of Our Amino Acid Library to Drive Drug-like Properties Directly from Selections ➢ Over 3,000 Amino Acids currently in our PDPS and Optimization Libraries ✓ Backbone Diversity ✓ Side Chain Diversity ✓ Increase Solubility ✓ Decrease PPB ✓ Reduce HBD ✓ Increase Stability Intracellular Delivery Peptide-Drug Conjugates Fluorinated Cyclic N-Substituted Bulky Ether Side Chain α,α-Disubstituted 2024 New Addition Examples Oral/Injectable Peptide Therapeutics
Page 42
42 Sequence space in PDPS Synthesized peptide Frequency 2025+ >100M Sequences 96+ Selections ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% Automated PDPS ~6M Sequences 96 Selections Manual PDPS <2M Sequences 8 - 16 Selections ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 74535 ClAc F X1 X1 X2 X2 X1 X2 X1 X1 X3 X1 X1 C 0.46% 5.03% 74529 ClAc F X2 X3 X3 X1 X2 X2 X2 X1 X1 X3 X2 X1 X1 C 2.84% 4.51% 74530 ClAc F X1 X3 X3 X1 X2 X1 X2 X1 X1 X2 X2 X1 X4 C 1.91% 1.90% 74541 ClAc F X1 X1 X1 X3 X2 X2 X1 X1 X3 X1 X3 C 0.23% 1.85% 74544 ClAc F X2 X1 X3 X2 X1 X5 X4 X5 X1 X1 X2 X3 X2 C 0.16% 1.39% 74532 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X4 X2 X1 X1 C 0.96% 1.37% 74531 ClAc F X2 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X4 C 0.98% 1.13% 74563 ClAc F X1 X2 X2 X1 X1 X2 X1 X1 X1 X1 X1 C 0.09% 0.84% 74534 ClAc F X2 X3 X2 X1 X3 X1 X2 X2 X1 X4 X1 X1 X4 C 0.44% 0.74% 74555 ClAc F X1 X2 X3 X3 X1 X2 X2 X1 X3 X4 X1 C 0.11% 0.72% 74533 ClAc F X1 X3 X3 X1 X1 X1 X2 X1 X1 X3 X1 X1 X1 C 0.59% 0.62% 74549 ClAc F X4 X2 X1 X2 X1 X3 X1 X2 X4 X1 X1 X3 X5 C 0.06% 0.39% 74536 ClAc F X4 X3 X3 X1 X3 X1 X2 X1 X1 X3 X1 X1 X4 C 0.31% 0.29% 74540 ClAc F X1 X3 X2 X1 X3 X2 X2 X1 X1 X3 X2 X1 X1 C 0.28% 0.26% 74537 ClAc F X1 X3 X2 X1 X1 X1 X2 X1 X1 X4 X1 X1 X4 C 0.19% 0.24% 74573 ClAc F X1 X2 X3 X1 X1 X3 X1 X1 X3 X1 X1 C 0.07% 0.24% 74538 ClAc F X2 X3 X3 X1 X2 X3 X2 X1 X1 X3 X2 X1 X4 C 0.29% 0.23% 74542 ClAc F X2 X3 X1 X1 X3 X1 X2 X2 X1 X4 X2 X1 X1 C 0.15% 0.18% 74562 ClAc F X1 X2 X1 X1 X3 X1 X3 X2 X1 X3 X3 X4 X1 C 0.10% 0.17% 74547 ClAc F X2 X3 X3 X1 X3 X1 X2 X2 X1 X1 X2 X1 X1 C 0.18% 0.17% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 75348 ClAc F X1 X2 X3 X1 X3 X3 X1 X2 X4 X1 C 0.69% 3.00% 75349 ClAc F X2 X1 X2 X1 X1 X3 X3 X1 X2 X4 X2 X2 X1 C 0.62% 2.97% 75347 ClAc F X4 X1 X3 X1 X1 X3 X1 X3 X4 X3 X1 C 1.06% 2.39% 75506 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X1 C 0.10% 1.82% 75353 ClAc F X2 X1 X2 X2 X1 X4 X2 X2 X2 X4 X1 X3 X2 C 0.50% 1.66% 75545 ClAc F X4 X2 X2 X1 X1 X2 X5 X1 X3 C 0.03% 1.46% 75561 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.03% 1.29% 75593 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X3 C 0.03% 1.02% 75664 ClAc F X4 X2 X2 X1 X2 X2 X5 X1 X1 C 0.02% 0.87% 75626 ClAc F X2 X2 X2 X1 X2 X2 X5 X1 X2 C 0.02% 0.76% 75350 ClAc F X1 X2 X1 X4 X1 X1 X2 X4 X2 X3 X3 C 0.24% 0.66% 75357 ClAc F X4 X2 X2 X1 X3 X1 X1 X1 X5 X4 X1 X1 C 0.35% 0.62% 75356 ClAc F X4 X3 X3 X1 X2 X2 X1 X2 X4 X3 X1 C 0.32% 0.50% 75352 ClAc F X2 X2 X1 X2 X1 X1 X2 X2 X3 X1 C 0.31% 0.49% 75364 ClAc F X1 X2 X2 X1 X3 X3 X2 X2 X3 X4 X2 C 0.27% 0.49% 75355 ClAc F X2 X2 X2 X1 X3 X2 X2 X2 X4 X2 C 0.27% 0.49% 75351 ClAc F X2 X2 X1 X3 X1 X1 X3 X4 X2 X5 X2 C 0.34% 0.46% 75354 ClAc F X2 X4 X1 X2 X5 X1 X3 X4 X3 X1 C 0.30% 0.36% 75367 ClAc F X4 X1 X2 X1 X4 X2 X1 X3 X4 X3 X1 C 0.26% 0.11% ID Sequence %Frequency 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Rd5 K2 76693 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 8.21% 8.98% 76692 ClAc F X1 X2 X2 X3 X1 X2 X3 X2 X1 X3 X4 X1 C 12.12% 8.26% 76698 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X4 X1 C 1.27% 1.09% 76697 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 1.45% 1.08% 76694 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X1 C 2.70% 0.95% 76696 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X3 X2 X1 C 1.83% 0.82% 76723 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.21% 0.67% 76695 ClAc F X2 X2 X3 X1 X1 X5 X5 X1 X4 X2 X3 X2 C 2.11% 0.67% 76727 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X3 C 0.14% 0.53% 76704 ClAc F X3 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 C 0.66% 0.42% 76700 ClAc F X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.77% 0.40% 76702 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.74% 0.39% 76703 ClAc F X3 X2 X1 X2 X2 X4 X3 X5 X3 X1 X4 C 0.63% 0.39% 76726 ClAc F X2 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.15% 0.28% 76933 ClAc F X2 X2 X4 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.05% 0.24% 76737 ClAc F X4 X2 X2 X1 X1 X2 X3 X2 X1 X1 X2 X1 C 0.08% 0.23% 76701 ClAc F X2 X2 X1 X1 X3 X3 X2 X1 X1 X2 X3 C 0.86% 0.20% 76707 ClAc F X1 X2 X2 X1 X1 X3 X3 X2 X1 X1 X4 X1 X5 C 0.65% 0.18% 76699 ClAc F X3 X3 X1 X5 X1 X3 X3 X2 X2 X3 X2 X1 X2 C 0.83% 0.06% 0 1 2 4 6 5 3 7 8 9 Dataset Acquisition ✓ Increase sequence depth ✓ Identify diverse starting points Computational Methodologies ✓ Predict drug-like properties ✓ Reduce optimization cycle time NCAA Peptide Clustering Algorithm ML PhysChem Property Models PPB Solubility Stability Hot Spot Prediction Large Language Models Generative peptide design A da MeA F df MeF Y dy MeY A 8 4 3 -1 -2 -2 -2 -4 -3 da 4 8 1 -3 -1 -5 -3 -2 -5 MeA 3 1 8 -3 -5 0 -4 -6 -1 F -1 -3 -3 8 1 2 4 -3 -2 df -2 -1 -5 1 8 0 -3 4 -3 MeF -2 -5 0 2 0 8 -2 -3 4 Y -2 -3 -4 4 -3 -2 8 2 3 dy -4 -2 -6 -3 4 -3 2 8 1 MeY -3 -5 -1 -2 -3 4 3 1 8 Score matrix 2025+ Today Enhancing Our Data Acquisition and Analysis Pipeline to Develop ML/AI Methods Source: *) Nature Computational Science volume 2, pages378–386 (2022) *
Page 43
43 Reduction of cycle times and will increase our success rate of moving our programs into the clinic Selections PDPS Optimization Drug-like Amino Acids Automation ML/AI Next Generation Synthetic Methods Med Chem Optimization in vivo Efficacy & Safety Oral Injectables Ac Cu Small Molecules Oligonucleotides RI Diagnostics RI Therapeutics PDPS 2024: 3 - 7 Cycles 2025 Ambition: 2 - 3 Cycles
Page 44
44 Mission of PeptiDream Group Discovering the next generation of transformational medicines